Breakthrough Antibody 007 Offers New Hope Against HIV-1

HIV-1 can be neutralized by antibodies that bind to vulnerable structures on the virus surface. One such site is the V3 glycan site of the viral envelope protein, which is critical for virus entry into human cells. This site has been a key focus for developing new immunotherapeutic and preventive strategies. However, most previously identified antibodies effectively recognize the V3 glycan site in only a subset of circulating HIV variants.

Novel Antibody 007 Targets V3 Glycan Site Differently

A newly described antibody, designated 007, targets the V3 glycan site differently from existing antibodies. Unlike classical V3 antibodies, its binding does not rely on a specific sugar structure that HIV-1 frequently alters to evade immune responses. This unique mechanism positions 007 as a promising advancement.

Laboratory tests demonstrated that 007 remains effective against virus variants resistant to classical V3 antibodies. In a mouse model with human immune cells, 007 also enhanced existing V3 antibody therapy, compelling the virus to develop multiple simultaneous changes for escape.

A key study finding indicates that 007 closes existing activity gaps of classical V3 antibodies, thereby supporting antibody therapy combinations that neutralize the virus more effectively.

Expert Perspectives on Therapeutic Potential

Dr. Lutz Gieselmann, a first author of the study, commented on the site's previous underutilization:

"The V3 glycan site, while considered a vulnerable epitope of HIV-1, had been only partially exploited therapeutically and for vaccine development until now."

Dr. Malena Rohde, also an author, highlighted the versatility of the new approach:

"The identification of antibody 007 shows this weak point can be targeted more versatilely, opening new perspectives for vaccine development."

These research findings are significant for the development of new combination therapies and vaccines.

Development and Support

Antibody 007 has been exclusively licensed to Vir Biotechnology, in partnership with the Gates Foundation, for use in HIV immunotherapy. It is currently in preclinical development with support from the Cologne-based start-up Togontech.

The study received support from the Gates Foundation, the German Research Foundation (DFG), the German Center for Infection Research (DZIF), and the European Research Council (ERC).